Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies

The prognosis for children and adolescents with rhabdomyosarcoma (RMS) has improved with refinements in multi‐modal therapy. Since 1972, the Intergroup Rhabdomyosarcoma Study Group (now the Children's Oncology Group Soft‐Tissue Sarcoma Committee) has conducted serial studies for RMS. This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies. Pediatr Blood Cancer 2012; 59: 5–10. © 2012 Wiley Periodicals, Inc.

[1]  C. Ahern,et al.  A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  James R. Anderson,et al.  Rhabdomyosarcoma in infants younger than 1 year , 2011, Cancer.

[3]  J. Meza,et al.  Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group , 2011, Pediatric blood & cancer.

[4]  J. Meza,et al.  Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  James R. Anderson,et al.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Hunger,et al.  Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) , 2010 .

[7]  James R. Anderson,et al.  Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Keir,et al.  Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.

[9]  S. Donaldson,et al.  Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG). , 2010 .

[10]  James R. Anderson,et al.  Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). , 2010 .

[11]  O. Delattre,et al.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Marvin D Nelson,et al.  Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study , 2010, Pediatric blood & cancer.

[13]  James R. Anderson,et al.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Eary,et al.  [F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults , 2009, Cancer.

[15]  A. Ferrari,et al.  Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Sorensen,et al.  Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. , 2009, The American journal of pathology.

[17]  T. Thompson,et al.  Cancer Incidence Among Children and Adolescents in the United States, 2001–2003 , 2008, Pediatrics.

[18]  D. West,et al.  Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT) , 2008 .

[19]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Rini,et al.  Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin , 2008, Clinical Cancer Research.

[21]  Thomas Völker,et al.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  James R. Anderson,et al.  Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Xiang,et al.  Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma , 2007, Modern Pathology.

[24]  P. Sorensen,et al.  Correlation Between Histology and PAX/FKHR Fusion Status in Alveolar Rhabdomyosarcoma: A Report From the Children's Oncology Group , 2007, The American journal of surgical pathology.

[25]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[26]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  James R. Anderson,et al.  Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Helman,et al.  CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. , 2006, Neoplasia.

[30]  J. Eary,et al.  [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. B. Marsden,et al.  Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  James R. Anderson,et al.  Rhabdomyosarcoma: many similarities, a few philosophical differences. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Eary,et al.  Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy , 2005, Cancer.

[34]  A. Ferrari,et al.  Vinorelbine and low‐dose cyclophosphamide in the treatment of pediatric sarcomas , 2004, Cancer.

[35]  J. Meza,et al.  Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. , 2004, International journal of radiation oncology, biology, physics.

[36]  W. Meyer,et al.  Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  James R. Anderson,et al.  Age is an independent prognostic factor in rhabdomyosarcoma: A report from the soft tissue sarcoma committee of the children's oncology group , 2004, Pediatric blood & cancer.

[38]  Peter Bohlen,et al.  A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. , 2003, Cancer research.

[39]  B. Bernardi,et al.  Rhabdomyosarcoma in infants younger than one year old , 2003, Cancer.

[40]  A. Ferrari,et al.  Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  James R. Anderson,et al.  What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract? , 2001, Cancer.

[43]  L. Diller,et al.  High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood , 2001, Cancer.

[44]  D. Eberhard,et al.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.

[45]  M. Tan,et al.  Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  G. Henze,et al.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Pappo,et al.  Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  P. Houghton,et al.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  W. Meyer,et al.  #407 Children from ethnic minorities have benefited equally as other children from contemporary therapy for rhabdomyosarcoma (RMS): a report from the intergroup rhabdomyosarcoma study group (IRSG) , 1999 .

[50]  L. Helman,et al.  Rhabdomyosarcoma: an overview. , 1999, The oncologist.

[51]  P. Voûte,et al.  Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. , 1998, European journal of cancer.

[52]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[53]  James R. Anderson,et al.  Pretreatment TNM staging of childhood rhabdomyosarcoma , 1997, Cancer.

[54]  H. B. Marsden,et al.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification‐an intergroup rhabdomyosarcoma study , 1995, Cancer.

[55]  A. Pappo,et al.  Biology and therapy of pediatric rhabdomyosarcoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  E. Gehan,et al.  Hyperfractionated radiation in children with rhabdomyosarcoma--results of an Intergroup Rhabdomyosarcoma Pilot Study. , 1995, International journal of radiation oncology, biology, physics.

[57]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Michael E. Phelps,et al.  Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose , 1993, Journal of computer assisted tomography.

[59]  P. Houghton,et al.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. , 1993, Cancer research.

[60]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.

[61]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  H. Shimada,et al.  Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  H. Maurer.  The intergroup rhabdomyosarcoma study , 1982 .